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ABSTRACT 
 
The fourth scientific workshop of the European Crohn's and Colitis Organization (ECCO) 
focused on the relevance of intestinal fibrosis in the disease course of inflammatory bowel 
disease (IBD). The objective was to better understand the pathophysiological mechanisms of 
intestinal fibrosis, to identify useful markers and imaging modalities of fibrosis in order to 
assess its presence and progression, and, finally, to point out possible approaches for the 
prevention and the treatment of fibrosis. 
 
The results of this workshop are presented in three separate manuscripts. This first section 
describes the most important mechanisms that contribute to the initiation and progression of 
intestinal fibrosis in IBD including the cellular and molecular mediators, the extracellular 
matrix molecules and matrix metalloproteinases/tissue inhibitors of metalloproteinases-
system, the microbiota products, the role of fat, genetic and epigenetic factors, as well as the 
currently available experimental models. Furthermore, it identifies unanswered questions in 
the field of intestinal fibrosis and provides a framework for future research. 
 
 
KEYWORDS: Inflammatory bowel disease, ulcerative colitis, Crohn‟s disease, intestinal 
fibrosis, extracellular matrix, matrix metalloproteinases, tissue inhibitors of 
metalloproteinases, microbiota, mesenteric adipose tissue, genetics, epigenetics, animal 
models. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 3 
CONTENTS 
1. Introduction 
2. Cellular and molecular mediators of intestinal fibrosis 
2.1 Renin-angiotensin system(RAS) 
2.2 Integrins 
2.3 Mammalian target of rapamycin(mTOR) 
2.4 Peroxisome proliferator activator receptors(PPARs) 
2.5 Pathogen-associated molecular patterns(PAMPs)and toll-like receptors(TLRs)  
2.6 Damage-associated molecular patterns (DAMPs) 
2.7  ECM components 
2.8 Hedgehog signalling 
2.9 Wnt/β-catenin signalling 
2.10 Klotho proteins 
2.11 Receptor for advanced glycation endproducts (RAGE) 
2.12 Notch signalling 
2.13 microRNAs 
2.14  Endoplasmic reticulum (ER) stress 
2.15 Telomere shortening 
3. ECM molecules and MMP/TIMP system 
3.1  Extracellular Matrix (ECM) proteins 
3.2  Matrix metalloproteinases (MMPs)/tissue inhibitors of metalloproteinases 
(TIMPs)-system  
4. Microbiota products  
4.1 Microbiota in IBD 
4.2 Genetic influences  
4.3 Microbiome effects 
5. Adipose tissue 
5.1 Creeping Fat 
5.2 Adipose-tissue macrophages 
5.3 Adipocytes and microbial translocation 
5.4 Adipocytes and Adipokines  
5.5 Adipocytes and PPARγ  
6. Genetic and epigenetic factors 
6.1 Genetics  
6.2 Epigenetics 
7. Animal models 
7.1 Spontaneous Intestinal Fibrosis  
7.2 Chemically-Induced Models  
7.3 Bacteria-Induced Models  
7.4 Immune-Mediated Models 
7.5 Radiation-Induced Intestinal Fibrosis 
7.6 Post-operative models of fibrosis 
7.7 Gene Knockout and Transgenic Models 
8. Conclusions 
 
Conflict of interest  
Acknowledgments  
References 
  
 4 
1. INTRODUCTION 
 
Fibrogenesis is a “physiological process” triggered by inflammation that may lead to tissue 
repair or fibrosis depending on the balance between production and degradation of 
extracellular matrix(ECM) proteins(1). Fibrosis occurs when regeneration and repair fail to 
restore normal tissue architecture and can lead to organ malfunction and death. Although 
fibrosis is increasingly recognized as a problem, there are few, if any, treatment strategies 
available. Fibrosis is a common problem in inflammatory bowel disease(IBD) but which 
factors trigger chronicity and promote fibrosis is not known(2,3).  
 
Inflammation is necessary for fibrosis, but it subsequently plays a minor role in its 
progression and anti-inflammatory treatment in IBD may not prevent fibrosis once excessive 
ECM deposition has started(4). Mechanisms that regulate fibrosis, therefore, appear to be 
distinct from those regulating inflammation. Fibrosis, however, follows the distribution of 
inflammation. In ulcerative colitis (UC), ECM deposition is restricted to the colonic mucosal 
and submucosal layers. In CD, fibrosis can involve the full thickness of the bowel and result 
in luminal narrowing. Intestinal fibrosis, however, displays significant variability among IBD 
patients suggesting that fibrosis susceptibility may have a genetic component with 
conditioning by environmental and intestinal microbial factors(2). 
 
Despite therapeutic advances in IBD, none prevent, nor reverse, established strictures(4). This 
implies that controlling inflammation may only partially affect fibrosis. The lack of any anti-
fibrotic drugs is partly due to the main, and specific cellular and molecular fibrosis pathways 
remaining unidentified. New and improved preclinical animal fibrosis IBD models are thus 
needed(5). Anti-fibrotic drug development is also hindered by the unpredictable evolution of 
fibrosis as a clinical benefit may only be observed after prolonged treatment making clinical 
trials long and expensive.  
 
To design effective anti-fibrotic drugs, fibrosis needs to be viewed as a pathological process 
distinct from inflammation. Understanding the mechanisms leading to intestinal fibrosis may 
thus pave the way for new anti-fibrotic agents(4). In this review, we describe the most 
important mechanisms that contribute to the initiation and progression of intestinal IBD 
fibrosis including the cellular and molecular mediators, the ECM molecules and matrix 
metalloproteinases(MMPs)/tissue inhibitors of metalloproteinases(TIMPs)-system, the 
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microbiota products, the role of fat, genetic and epigenetic factors, as well as the currently 
available experimental models. 
 
Key points 
 Intestinal fibrosis is common in IBD; 
 Fibrosis is defined by excessive ECM; 
 Fibrosis occurs as a consequence of inflammation and follows its distribution; 
 Inflammation is necessary to trigger fibrosis, but may have a minor role in its 
progression; 
 Therapeutic control of intestinal inflammation may not affect fibrogenesis; 
 Fibrosis is a chronic and progressive process acting through complex 
cell/matrix/cytokine and growth factors interactions, but may be reversible; 
 Understanding of the mechanisms behind intestinal fibrosis may pave the way for new 
anti-fibrotic agents. 
 
2. CELLULAR AND MOLECULAR MEDIATORS OF INTESTINAL FIBROSIS  
 
Intestinal fibrosis is no longer considered inevitable and irreversible(1,2). Myofibroblast 
activation is a common feature in fibrosis and research of the innate and adaptive immune 
responses in IBD participate in the differentiation/activation of myofibroblasts(2). The Th17-
type immune response is proinflammatory/profibrotic. Th2-type immunity, defined by 
interleukin(IL)-4, -5 and -13 production is also fibrogenic with IL-13 being the dominant 
mediator. By contrast, Th1-type immunity expressing interferon-γ(IFN-γ) has anti-fibrotic 
activity. A detailed overview of how the immune mediators affect fibrotic disease of other 
organs, including liver, lung, skin and kidney, has been recently published and shall not be 
covered further here(1). 
 
While in other organs the source of ECM-producing myofibroblasts is restricted to a few cell 
types, in the intestine multiple cell types may become activated myofibroblasts(2,4). These 
cells derive not only from resident mesenchymal cells (fibroblasts, sub-epithelial 
myofibroblasts[SEMFs] and smooth muscle cells[SMCs]) but also from epithelial and 
endothelial cells (via epithelial [EMT]/endothelial-mesenchymal transition [EndoMT]), 
stellate cells, pericytes, and bone marrow stem cells(2,4) (Figure 1).  ECM-producing cells are 
activated by paracrine signals, autocrine factors, and pathogen-associated molecular patterns 
(PAMPs) derived from microorganisms that interact with pattern recognition receptors 
(PRRs) such as toll-like receptors(TLRs)(2). Myofibroblasts are also activated by products 
derived from injured cells, the „so-called‟ damage-associated molecular patterns(DAMPs) 
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including DNA, RNA, ATP, high-mobility group box proteins(HMGB), microvesicles, and 
fragments of ECM molecules(2).   
 
All intestinal ECM-producing cells act synergistically and are controlled by numerous 
molecular mediators(1,4) (Table 1). The most important include transforming growth factor-β 
(TGF-β), activins, connective tissue growth factor(CTGF), platelet-derived growth factor 
(PDGF), insulin-like growth factor(IGF-1&2), epidermal growth factor(EGF), endothelin(ET-
1, -2, -3), various cytokines, products of oxidative stress, components of the renin-angiotensin 
system(RAS), angiogenic factors(e.g. vascular endothelial growth factor-VEGF) and 
mammalian target of rapamycin(mTOR)(4). Soluble factors with anti-fibrotic properties have 
also been identified including peroxisome proliferator activated receptors(PPARs), IFN-, 
IFN-, IL-7, IL-10, IL-12, Smad7, adiponectin and nitric oxide(NO).  
 
Although the TGF-/Smad pathway represents the major driving force of fibrosis, several 
pro-fibrogenic and anti-fibrogenic molecules seem to interact directly with the TGF-β/Smad 
pathway (Figure 2). The effect of these mediators on the TGF-/Smad 'core pathway' have 
been extensively discussed in a recent review(4). The pharmacological modulation of ECM 
deposition by reducing ECM-producing cell activation and/or by modulation of specific 
molecular mediators could thus modify intestinal fibrosis(1,2,4). 
 
Blockade of TGF signalling, either at the extracellular, or intracellular, level offers a strategy 
to prevent/treat fibrosis(1,4). Since TGFβ, however, is also involved in cellular 
differentiation, proliferation, transformation and immunoregulation, its blockade is 
problematic as TGF, Smad2 and Smad4 disruptions are lethal. Targeting of individual 
intracellular mediators, however, could lead to the selective blockade of TGF fibrotic 
responses without involving physiologically vital TGF responses(Figure 3). Disrupting 
Smad3 results in mice that survive to adulthood and also confers resistance to tissue 
fibrosis(4). Hepatic growth factor(HGF), bone morphogenetic protein(BMP-7) and decorin 
are three natural inhibitors of the TGF/Smad pathway and demonstrate anti-fibrotic effects. 
 
In addition to the most common pro-fibrotic mediators including several growth factors, 
cytokines, chemokines and reactive oxygen species(ROS), new inducing and modulators 
factors of fibrosis are emerging (Table1). These include RAS, integrins, mTOR, PPARs, 
PAMPS, TLRs, DAMPs, ECM fragments, Hedgehog (Hh) signalling and Wnt/-catenin and 
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Klotho pathways, receptor for advanced glycation endproducts (RAGE), Notch signalling 
pathway, microRNAs (miRNAs), as well as endoplasmic reticulum (ER) stress and telomere 
shortening.  
 
2.1 Renin-angiotensin system (RAS) 
The RAS regulates cell growth, differentiation, proliferation and apoptosis, ROS generation, 
cytokine expression, endothelial cell activation, inflammation, ECM production and 
fibrosis(6). All components of the RAS exist in the intestine. Angiotensin II(ANGII), the 
principal effector of RAS, participates in fibrosis through the regulation of the 
inflammatory/fibrotic processes. ANGII is increased in CD intestine. Intestinal fibrosis is 
significantly improved, or even reversed, by Angiotensin converting enzyme(ACE) inhibitors 
and AT1 receptor antagonists, findings that closely correlate to reduced TGF-1 and CTGF 
expression(7).  
 
2.2 Integrins 
Integrins regulate cell and ECM interactions and influence fibrosis(4). In normal conditions 
αvβ6 integrin is not expressed, but is up-regulated and co-localises with TGF- following 
tissue injury(8). αvβ6 activates latent TGF-, while various genetic and pharmacologic 
interventions targeting it reduce TGF-β1 activation and fibrosis(9). Inhibitors of αvβ6 
significantly reduce tissue levels of pro-fibrogenic transcripts, including procollagen α1, α-
SMA, TGF-β1, TGF-β2, CTGF, TIMP-1 and αvβ6 itself. Inhibition αvβ6 integrin could thus 
impact fibrosis, through local TGF- inhibition without affecting vital homeostatic TGF 
roles(4).  
 
2.3 Mammalian target of rapamycin(mTOR) 
mTOR, a phosphatidylinositol 3-kinase-related kinase,
 
forms at least two distinct 
complexes(10). The mTOR complex 1(mTORC1) is composed of mTOR, GβL and Raptor 
and controls protein synthesis, cell growth/proliferation, autophagy, angiogenesis and fibrosis. 
The mTOR complex 2(mTORC2) consists of mTOR, GβL and Rictor and is involved in cell 
proliferation and survival, metabolic regulation and actin cytoskeleton organization. mTOR 
signalling is activated by hormones, growth factors, amino acids, stress and alterations in 
cellular energy status. mTOR inhibitors(mTORis) have anti-fibrotic activities, reduce 
fibroblast/myofibroblast numbers and down-regulate pro-fibrogenic cytokine production.  
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Defective autophagy and angiogenesis may cause fibrosis. Control of angiogenesis and 
lymphangiongenesis, might improve fibrosis, particularly due to the connection between 
vascular remodelling and fibrogenesis in chronic inflammation(11). VEGF expression is 
increased in IBD and its blockage reduces fibrosis in animal models. 
 
mTOR regulates hypoxia-inducible factor(HIF)1-α, VEGF and angiopoietin-2 expression, the 
main driving factors of neo-angiogenesis. TGFβ/Smad3 also activates mTORC1 and 
promotes collagen production by increasing HIF-1α and mTORC1 inhibition prevents TGF-β-
induced HIF expression and fibrosis(12). The combined immunosuppressive and anti-fibrotic 
action of mTOR inhibitors like rapamycin, and its analogues, sirolimus and everolimus, are 
thus potential treatments in CD fibrosis.  
 
2.4 Peroxisome proliferator activator receptors(PPARs) 
PPARs are nuclear receptors which regulate gene transcription(13). PPAR- is present in 
colorectal mucosa and in adipocytes, monocytes, macrophages, dendritic, B and T cells. It 
modulates adipocyte differentiation, glucose homeostasis, lipid metabolism, 
inflammatory/immune processes and fibrosis. PPAR-γ activation strongly correlates with the 
TGF-β/Smad pathway as it directly antagonises Smad3, or down-regulates CTGF expression 
(Figure 2)(14). It also prevents the increase in profibrotic MMP-2, MMP-9, TIMP-1, PDGF 
and leptin activities(15,16). Reduced PPARs expression induces increased collagen 
production and fibrosis progression, whereas its overexpression prevents fibrosis(17). PPAR- 
has received particular attention in recent years as its activation, both by natural and synthetic 
agonists, attenuates fibrosis in several organs including the intestine, and these anti-fibrotic 
effects are abolished by PPAR- selective antagonists(13,18). PPAR- is thus an innate 
protector against excessive fibrogenesis and a potential anti-fibrotic target in IBD. 
 
2.5 PAMPs and TLRs  
Many fibrotic disorders have an infectious aetiology(19).  In IBD, luminal bacteria are 
pathogenic and express PAMPs  that activate immune and non-immune cells.  PAMPs include 
lipopolysaccharide (LPS), bacterial DNA, and double-stranded RNA, and these bind to PRRs 
like TLRs(2). 
 
TLRs act as microbial product sensors that trigger host defense and activate immune and both 
pro-inflammatory and pro-fibrotic gene expression. TLR activation is pivotal in IBD, 
suggesting that TLR over-expression could underlie abnormal host reactions to commensal 
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bacteria in IBD.  CD patients with antibodies directed against microbial peptides develop 
earlier fibrostenotic disease(20). This defective immune tolerance to commensal bacteria 
suggests that an aberrant innate immune response is involved in intestinal fibrogenesis.  
 
TLR expression in non-immune cells is a key event leading to fibrosis. Increased expression 
of TLR2, -3, -4, -6 and -7 occurs in CD and promote fibroblast differentiation into 
myofibroblasts and ECM expression(21).  
 
The major NOD2 polymorphisms associated with CD produce defects in host defense against 
invading bacteria leading to persistent intracellular infection(20). NOD2 is expressed by 
Paneth cells with a correlation between NOD2 variants and down-regulation of mucosal α-
defensin. NOD2 gene variants in CD with/without variants of TLRs (TLR4) or ATG16L1 
have an increased risk of small bowel (SB) fibrostenosis(20) (Figure 4).  
 
2.6 DAMPs 
Activation of immune and non-immune cells can occur by products from injured cells, the 
DAMPs that promote inflammation. DAMPS include a wide range of products (DNA, RNA, 
ATP, HMGB1, ECM fragments, interleukins etc) which cause sterile inflammation, but 
whether DAMPs promote fibrosis is unclear(2). One of the best-characterized DAMPs is the 
HMGB1. Ethyl pyruvate inhibits HMGB1 release and decreases inflammation, ameliorates 
colitis and reduces intestinal cytokine production in IL-10
-/-
 mice, while HMGB1 activation of 
the induced RAGE promotes NF-κB and MAP kinase signalling, resulting in 
inflammation(22). The HMGB1/RAGE pathway regulates metabolism and autophagy in 
experimental colitis and HMGB proteins function as universal sentinels for nucleic acid-
mediated innate immune responses(23). 
 
2.7 ECM components 
ECM regulates inflammation, healing and fibrosis(1). Intestinal ECM acts as a reservoir for 
pro-fibrotic factors, cytokines and chemokines. TNF-, TGF- and bFGF interact with 
various ECM moieties, while ECM fragments bind to, and activate, TLR2 and TLR4. Fibrin, 
collagen IV and laminin fragments, modulate cell migration and proliferation, while fibrin 
and fibronectin promote EMT. Hyaluronan is essential for TGF-β-induced myofibroblast 
differentiation and induces pro-inflammatory/fibrotic cytokine expression and MMP 
secretion(24).  
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2.8 Hedgehog signalling 
The Hedgehog(Hh) signalling pathway regulates fibrosis and progenitor cell proliferation and 
differentiation. It is pro-fibrotic and promotes myofibroblast activation, EMT, MMP release, 
TGF-β1 and ECM production(25). Conversely, Hh signalling inhibition is potently anti-
fibrotic in preclinical models of fibrosis(26).  
 
2.9 Wnt/-catenin  
The Wnt-β-catenin signalling pathway regulates cell growth, tumourigenesis and is activated 
in fibrosis. Activation of Wnt-β-catenin signalling promotes EMT and is required for TGF-β-
mediated fibrosis(27). Involvement of the α3β1 integrin occurs in the crosstalk between TGF-
β1 and Wnt signalling. TGF-β stimulates canonical Wnt signalling in a p38-dependent 
manner by decreasing the expression of the Wnt antagonist Dickkopf-1(DKK-1). In addition, 
hypermethylation of DKK1 promotors lead to aberrant Wnt signalling representing a link 
between epigenetic alterations and Wnt signalling in fibrosis(28).  Wnt signalling increases 
ECM synthesis, T cell transmigration and regulates MMP-2, -7 and -9. Inhibition of Wnt-β-
catenin signalling reverses ﬁbrosis. 
 
2.10 Klotho 
Klotho family of membrane proteins function as obligate co-receptors for some fibroblast 
growth factors(FGFs)(29). The extracellular domain of Klotho protein is subject to 
ectodomain shedding and is released into circulation to act as an endocrine factor. Unlike 
membrane Klotho, which functions as a co-receptor for FGF23 to modulate FGF23 signal 
transduction, soluble Klotho is a multifunction protein present in biological fluids and impacts 
aging, energy metabolism, Wnt signaling inhibition, anti-oxidation, ion transport, RAS 
antagonism and fibrosis inhibition(30).  
 
Secreted Klotho protein directly binds to the type-II TGF-β receptor and inhibits TGF-β1 
receptor binding, TGF-β1 signalling and TGF-β1-induced EMT. In addition, secreted Klotho 
inhibits the Wnt and IGF-1 signalling that promotes EMT. Overexpression of Klotho 
abolished TGF-β1-induced fibrosis(30). 
 
2.11 RAGE 
This receptor for advanced glycation end products(AGEs) is fibrogenic, promotes EMT and 
ECM accumulation, increases activated myofibroblast numbers and up-regulates αSMA(31). 
In IBD, high RAGE expression correlates with disease activity and induces pro-inflammatory 
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mediators(32). Ligands inhibiting RAGE, by competing with AGE, could be therapeutic in 
IBD fibrosis.  
 
2.12 Notch signalling  
The Notch signalling pathway is essential to normal embryonic development, cellular 
proliferation and differentiation(33). Four Notch receptors and five ligands have been 
identified in mammals. Notch signalling is activated through the interaction of a Notch 
receptor with a ligand expressed on adjacent cells. The aberrant activation of this pathway 
induces fibrosis(34). Blocking Notch signalling with c-secretase inhibitors significantly 
attenuates fibrosis and decreases snail, vimentin, TGF-β1 and EMT(34). 
Notch signalling, particularly Notch1, cooperates with TGF-β in regulating FoxP3 expression 
during T regulatory cell (Treg) generation. Tregs are linked to fibrosis amelioration, although 
its specific role in fibrogenesis is less clear: it is plausible that Tregs could suppress Th17- 
and Th 2-driven fibrosis(35).  
 
2.13 miRNAs  
miRNAs are small, noncoding RNAs of 18-25 nucleotides that regulate gene and protein 
expression by repressing specific target genes post-transcriptionally. Over 80 miRNAs are 
implicated in fibrosis by modulating ECM remodeling, cell adhesion, inflammation, 
angiogenesis and EMT(36). miRNA-21 and miRNA-29 promotes fibrosis by regulating TGF-
β1/Smad and MAP kinase signalling, as well as CTGF and collagen expression. miRNA-192, 
miRNA-216a and miRNA-217, as miRNA-21, are key triggers of TGF-β and Smad3-driven 
fibrosis and miRNA-200a and miRNA-200b are involved in CD fibrosis(37).  
 
Some miRNAs like miRNA let-7d, miRNA-133, miRNA-30, miRNA-150, miRNA-194, and 
miRNA-200a are constitutively expressed in healthy tissues but down-regulate in fibrosis, 
suggesting an anti-fibrotic role. Specific miRNAs down-regulate Smad-3 activity and ECM 
expression, and prevent TGFβ-dependent EMT. miRNA-200 regulates TGF-β/Smad-induced 
EMT by controlling the Zinc finger E-box-binding homeobox 1 and 2 (ZEB1 and 2)(38). The 
miRNA changes in IBD and their specific role in fibrosis deserve further and more exhaustive 
investigations.  
 
2.14 Endoplasmic reticulum (ER) stress 
ER stress leading to apoptosis of key structural cells may regulate fibrosis(39). Excess 
accumulation of unfolded, or misfolded proteins in the ER activates cellular stress pathways. 
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ER stress is common in IBD(40). Genetic and environmental factors affect intestinal ER 
stress and inflammation(40). Genetic factors include either primary ER Stress (XBP1, AGR2, 
ORMDL3) or secondary ER stress (HLAB27, Mucins, ATG16L1). Environmental factors 
include bacteria, dietary and drugs. Induction of ER stress activates several EMT-related 
pathways, including TGF-β/Smads, Wnt/β-catenin, and Src(41). A better understanding of the 
mechanisms of ER stress could help in fibrosis prevention. 
 
2.15 Telomere shortening 
Telomere shortening impacts on pulmonary fibrosis and occurs with mutations in gene 
encoding telomerase reverse transcriptase, an enzyme crucial to the maintenance of telomere 
length(1). Pro-fibrotic mediators, like TGF-β1 and ROS, also participate in telomere 
shortening suggesting a vicious cycle among pro-fibrotic mediator production, impaired 
telomerase activity and fibrosis(42). Unfortunately, data on telomere shortening in IBD are 
lacking.  
 
Key points 
 Myofibroblasts derive from mesenchymal, epithelial, endothelial, and stellate cells, 
pericytes, and bone marrow stem cells; 
 ECM-producing cells act synergistically and are under numerous biological mediator 
control; 
 Blockage of selective signalling pathways can prevent/reverse intestinal fibrosis. 
Questions  
 What are the cellular triggers leading to fibrosis progression? 
 What is the main source of myofibroblasts in intestinal fibrosis? 
 What are the main mediators of myofibroblast activation? 
 What are the specific molecular markers of activated myofibroblasts? 
 Which factors determine the switch from inflammatory to fibrosing disease? 
 Can timing, concentration and the source of the main pro-fibrotic mediators affect their 
contribution to tissue remodelling/fibrosis? 
 Is the simultaneous action of pro-fibrotic mediators relevant to fibrogenesis?  
 Which factors represent the driving force (“core pathway”) of intestinal fibrosis? 
 Which factors with anti-fibrotic properties play a critical role in intestinal fibrosis? 
 
3. ECM MOLECULES AND MMP/TIMP SYSTEM 
 
Fibrogensis hinges on the balance between ECM deposition and degradation. If deposition 
outstrips degradation then fibrosis may occur, but if this balance can be modified then healing 
may proceed without fibrosis(3,43).  
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3.1 Extracellular Matrix(ECM) 
The intestinal ECM is comprised of structural proteins, particularly the collagens, specialized 
proteins, like vitronectin and fibronectin, and matricellular proteins, such as osteopontin and 
trombospondin(Table 2). Chronic intestinal inflammation leads to tissue damage with an 
increase in ECM turnover. ECM degradation is mediated by MMPs and the fine balance 
between MMPs and TIMPs appears to be disturbed in IBD(43). It is unclear, however, which 
specific MMPs and TIMPs are involved in fibrosis and how they are regulated.  
 
3.2 MMPs/TIMPs System 
MMPs are zinc- and calcium-dependent ECM degrading endopeptidases and collectively can 
degrade all ECM proteins. In addition, MMPs can proteolytically activate, or degrade, a 
variety of non-matrix substrates, including chemokines, cytokines, growth factors, and 
junctional proteins, which are usually secreted in an inactive preform.  
 
Depending on substrate specificity, amino acid similarity, and identifiable sequence modules, 
the MMPs can be classified into: collagenases, gelatinases, stromelysins, matrilysin, 
membrane-types and others(44) (Table 2). MMPs are regulated by two endogenous inhibitors, 
α2-macroglobulin and the TIMPs.  
 
MMPs are up-regulated in colitis models and IBD(43). MMP-9 and -3 are associated with 
mucosal damage and fistulae in CD, MMP-1, -3, and -13 with intestinal ulcers and MMP-10 
and -11 with epithelial dysfunction. In fibrosis, MMP-1 and collagen I, but not MMP-3 or 
collagen III, levels were elevated in the TNBS murine fibrosis model which parallel that in 
fibrosed CD(45). Mucosa overlying strictured fibrostenosing CD demonstrate higher TIMP-1 
levels and lower Smad7, MMP-12 and -3 expression than from mucosa overlying non-
strictured areas(46). 
 
Soluble mediators that are present in inflamed IBD modulate MMP and TIMP 
expression(2,4). TGF-β1 increases collagen secretion, decreases MMP-1 and increases 
TIMP1 production resulting in a net increase in collagen deposition. PDGF and IGF-1 also 
increase collagen production, but do not alter TIMP-1. IGF-1 decreases MMP-1 while PDGF 
increases its production. By contrast, enhanced cyclooxygenase(COX)-2 activity can block 
the pro-fibrogenic effects of TGF-β1 in SMCs and inhibit basal, and stimulated, levels of 
TIMP while inducing MMP secretion by macrophages. Activation of COX-2 also increases 
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prostaglandin(PG)-E2 production and an increase in PGE2 decreases fibroblast and SMC 
proliferation.  
 
Indomethacin, a non-specific COX inhibitor, induces intestinal inflammation and fibrosis in 
the TNBS mouse model(47). In this model PGE2 decreased intestinal inflammation and 
fibrosis and in PMA±Indomethacin-treated murine and human colonic fibroblasts, PGE2 
significantly decreased ECM deposition by decreasing TGFβ, collagen and TIMP expression, 
while increasing MMP expression. 
 
TIMPs inhibit MMPs(48). TIMP-1 and -3 are inducible, while TIMP-2 is constitutively 
expressed. A critical balance between MMPs and TIMPs maintains normal ECM 
homeostasis. An imbalance may enhance ECM deposition and fibrosis. Furthermore, TIMPs 
affect signalling and angiogenesis and TIMP-1 expression inversely correlates with pro-
inflammatory cytokine production, mucosal injury and disease activity(48). Increased TIMP-1 
levels occur in CD strictures(46).  
 
TIMP-3 is tightly bound to the surrounding matrix, is detected in normal and inflamed 
intestine and is expressed below ulcers and in the LP surrounding damaged crypts. The ratio 
between MMP-1/TIMP-1 and MMP-3/TIMP-1 is increased in inflamed IBD tissue and MMP-
3 levels are increased in fibroblasts and mononuclear macrophage-like cells with concomitant 
low levels of TIMP-1, TIMP-2 and TIMP-3 in intestinal CD fistulae(49). TGFβ1 down-
regulates MMP and enhances TIMP-1 expression.  
 
Conclusion 
MMPs and TIMPs are central to ECM turnover and actively regulate inflammation and 
remodelling. The net effect, however, is not dependent only on the MMP/TIMP balance, as 
functional receptors that mediate downstream signalling of TIMPs may provide additional 
perspectives for consideration when examining the role of MMPs and TIMPs in fibrosis.  
 
Key points 
 ECM components are active players in fibrosis; 
 MMP/TIMP balance alterations are observed in intestinal fibrosis; 
Questions  
 How do ECM components contribute to fibrosis? 
 What are the main sources of MMPs and TIMPs? 
 Which MMPs and TIMPs are most important? 
 How do MMPs and TIMPs contribute to intestinal fibrosis? 
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4. MICROBIOTA PRODUCTS  
 
The whole gut microbiome can be considered a true organ that is geared up for protecting 
our health and well-being and is amenable to modulation. Co-evolution of host and bacteria 
results in a symbiotic relationship, where the survival of harboured microbiota and human 
host is interdependent. 
 
While the microbiota is part of the internal gut microenvironment, this organ is subject to 
external macroenvironmental influences. The established concept is that all environmental 
elements may influence disease, and several environmental factors can influence immune 
responses leading to fibrosis. Given the enormity and diversity of the external environment, 
new tools and approaches are needed to evaluate the impact of the “exposome” on intestinal 
disease and fibrosis(2). 
 
The dominant mucosa-associated microbiota appears different from luminal faecal 
microbiota but is highly conserved in different intestinal segments. Bacteria residing in the 
mucous layer form a protective „living wallpaper‟ against exogenous bacteria through 
colonisation resistance. Once the gastrointestinal mucus layer is disrupted, bacteria directly 
contact with epithelial, dentritic, lymphocitic and stromal cells and endanger mucosal 
homeostasis. 
 
Chronic alteration of the intestinal mucosal barrier and microbiota may be critical in IBD 
pathogenesis, as well as in fibrosis(50,51). Molecular evaluation allows for the definition of 
“normal” microbiota, or normobiosis and exploring the dysbiosis in disease and its role in 
fibrosis.  
 
4.1 Microbiota in IBD 
Dysbiosis in IBD is characterized by increased bacterial density at the mucosal level, 
increased proportions of immuno-agressive commensals, reduced proportions of anti-
inflammatory commensals, and increased proportions of proteins that promote 
autoimmunity(51). Such dysbiosis creates a vicious circle favouring chronic inflammation. 
F. prausnitzii has anti-inflammatory properties which induces high IL10/IL12 cytokine 
release, reduces IL-1β and induces IL-8, and abolishes TNF-α induced NF-κB activity. The 
gut microbiota is involved in intestinal fibrogenesis by activating mesenchymal cells 
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through TLRs and NOD-like receptors, but not all bacterial products are pro-fibrogenic(2). 
 
4.2 Genetic influences  
Since microbial composition is established early in life, host genetics may impact on 
bacterial composition and the immune responses to commensal bacteria and mucosal barrier 
function(52,53). The possible mechanisms for genetic regulation of enteric microbiota 
include altered Paneth cell function and expression of antimicrobial peptides, altered mucus 
production, altered secretion of IgA and IgM, and altered innate and adaptive immune 
responses.  
 
Genes associated with CD include NOD2, that is linked to α-defensin production and  
intracellular bacteria clearance, ATG16L1, that is involved in autophagy and phagocytosis 
of bacteria, neutrophil cytosolic factor 4 (NCF4) that is involved in NADPH-mediated 
killing of phagocytosed bacteria, immunity-related GTPase family M protein (IRGM), 
which impacts on IFN-γ-induced killing of phagocytosed bacteria, and TLR4 that modulates 
the immune response toward bacteria. NOD2 polymorphisms, with/without TLR and 
ATG16L1 polymorphisms, increase SB fibrostenosis(20) (Figure 4). Patients with a stronger 
immune response to microbial peptides are also more likely to develop earlier complicated 
CD(20).  
 
4.3 Microbiome effects 
The persistence of exogenous, and endogenous stimuli, provided by infectious pathogens are 
major promoters of fibrosis(19). Thus an important role in fibrosis for the gut microbiota is 
suggested(51). Unfortunately very few models can study intestinal fibrosis in conjunction 
with the microflora(5). Although patients with NOD2 variants have more fibrosis, the 
NOD2 knock-down animal models, or animals overexpressing a variant corresponding to 
the human mutations, do not develop fibrosis(20). By contrast the spontaneous 
SAMP1/YitFc mouse model a CD-like chronic ileitis demonstrates fibrosis and these are 
abrogated under germ-free conditions.  
 
There is thus doubt to the role of the microbiome in fibrosis. One model used transplanted 
small intestine pieces into the neck fold of the same, or another, rat strain with TGF-β and 
other fibrosis mediators rapidly up-regulated and fibrosis developing within three 
weeks(54). The same model in mice confirmed the data but no differences in fibrosis 
between WT and Myd88-deficient mice were found, indicating that at least, under the 
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artificial conditions of this model, innate immune signalling was not central to the 
fibrosis(54). 
 
In liver fibrosis, impaired intestinal barrier function occurs with increased bacterial wall 
product translocation into the portal vein activating hepatic stellate cells(HSCs)(55). Cystic 
fibrosis also was influenced by bacterial stimuli as variants of the Cystic Fibrosis 
Transmembrane Resistance Protein (CFTR) were associated with faecal microbiota shifts, 
which aggravated the disease(56). These represent clear examples of microbial contribution 
to fibrosis. 
 
Conclusion 
The IBD microbiota is different, and markers of microbiota are associated with complicated 
CD.  It is unknown, however, if these differences are cause or effect. Nor is it known if they 
increase inflammation/fibrosis. It is thus important to study the relationship between fibrosis 
and IBD microbiota and determine if specific pro-fibrotic, or preventive microbial, 
compositions exist. This needs to be done knowing that there is huge variability in the 
human microbiome composition and that genetic risk factors for IBD may shape the 
microflora composition. Such studies will, therefore, need to be done in large cohorts of 
phenotypically well-characterized patients. 
 
Key points 
 Intestinal microbiota maintains intestinal mucosal barrier function but may also 
impair barrier function 
 Intestinal microbiota may impact IBD pathogenesis/fibrosis; 
 A dysbiosis occurs in IBD, which is different between CD and UC; 
 Serum markers for microbiota are associated with fibrostenotic CD. 
Questions  
 The microbiota affects intestinal inflammation, but does it affect fibrosis 
independently of inflammation? 
 Are there bacteria, or viruses, present in IBD that promote fibrosis without 
inflammation? 
 How do microbiotal products impact on myofibroblast activation? 
 
5. ADIPOSE TISSUE 
 
Adipose tissue is an energy regulator but also displays advanced endocrine and 
immunological properties. The latter occurs through its cellular composition that includes 
adipocytes, but also preadipocytes, macrophages, lymphocytes, fibroblasts and endothelial 
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cells. These cells generate a dense network of soluble factors that include adipokines, classical 
cytokines, chemokines, growth factors and hormones(57).  A role for mesenteric adipose 
tissue(MAT), the white adipose tissue(WAT) in IBD intestinal fibrosis is recognised(58). 
 
5.1 Creeping Fat 
In IBD, mesenteric fat is altered and may present as „creeping fat‟ or „fat wrapping‟ while 
„mesenteric obesity‟ can occur in CD(57). „Creeping fat‟ extends from the mesentery and 
covers at least 50% of the bowel circumference. These changes occur in >50% of CD 
patients. It correlates with inflammation severity with the terminal ileum most frequently 
involved. More interestingly, abnormal collagen deposition and stricturing are common 
findings in the bowel with fat wrapping suggesting a relationship between adipose tissue and 
fibrosis.  
 
5.2 Adipose-tissue macrophages 
Adipose tissue demonstrates unique functional characteristics, which may contribute to 
inflammation and fibrosis in IBD. Adipose tissue macrophages (ATMs) and T lymphocytes 
(ATTs) from active IBD release more IL-6, IL-4 and IL-13 than inactive disease and 
controls(59). A clear increase in the proportion of „alternatively activated‟ or M2 
macrophages is present in creeping fat(60). M2 macrophages are involved in tissue repair and 
collagen deposition(1). ATMs are under the constant influence of locally produced soluble 
mediators including adipokines(60). The functional importance of ATMs and ATTs, and the 
potential association with fibrosis, however, remains unclear.  
 
Pro-inflammatory mediators stimulate M1 macrophages, while M2 are polarised by Th2 
cytokines. Epigenetic changes and non-coding RNAs are involved in this process, as miR-155 
diminishes IL-13-induced M2 polarisation through reducing levels of IL-13. Mechanistic 
studies have demonstrated that M2 macrophages are not required for a Th2 response(1). 
Arg1-expressing M2 cells are required for the suppression and resolution of fibrosis as M2 
cells compete with Th2 cells and fibroblasts for l-arginine, which is required for the 
production of l-proline and collagen(61). Rather than promoting fibrosis, M2 cells inhibit 
ECM synthesis and fibrosis thus their role in fibrosis requires further investigation. 
 
5.3 Adipocytes and microbial translocation 
As fibrosis may be triggered by bacterial-derived factors it is important that adipocytes and 
preadipocytes bear functional PPRs, which elicit an immune response to microorganisms. In 
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addition, adipocytes may transform into macrophages and exert direct anti-microbial activity. 
This suggests that fat wrapping is an anti-microbial defense mechanism that isolates affected 
bowel to contain intraluminal bacteria spread and prevent bacterial translocation in mesenteric 
adipocytes in CD(62). „Creeping fat‟-induced intestinal fibrosis could be a mechanism for 
preventing bacterial spread.  
 
5.4 Adipocytes and Adipokines  
Adipocytes act as endocrine cells and, in IBD mesenteric adipose tissue and serum, secrete 
active pro- and anti-inflammatory molecules, known as adipocytokines or adipokines 
including leptin, adiponectin, resistin and ghrelin. Leptin is a cytokine-like protein that 
regulates immunity by promoting a Th1 profile, thus impacting CD pathogenesis(57,58).  
 
Adiponectin has a similar structure to TNF-α and antagonizes TNF-α by competing for the 
same receptor and demonstrates anti-inflammatory activity. Adiponectin down-regulates 
intercellular adhesion molecule-1(ICAM-1), endothelial adhesion molecule-1(ECAM-1) and 
E-selectin, thus inhibiting inflammatory cell migration and also regulates wound healing and 
fibrosis(63). While leptin is profibrogenic, and liver fibrosis is decreased in leptin- or leptin 
receptor deficient mice, adiponectin is, by contrast, anti-fibrogenic as extensive liver fibrosis 
may develop in adiponectin-knockout mice and is alleviated by administration of recombinant 
adiponectin(63). A potential anti-fibrotic effect of visceral mesenteric fat could relate to 
adipocytokine autophagy regulation.  
 
High levels of C1q/TNF-related protein-3(CTRP-3) expression occur in adipose tissue. 
CTRP3 is a paralog of adiponectin and a member of the CTRP superfamily. It is recognised 
as a novel adipokine widely expressed in CD(64). CTRP3 exerts anti-inflammatory/-
fibrogenic effects in human colonic fibroblasts inhibiting TGF-β release, reducing CTGF 
expression and collagen production. 
 
5.5 Adipocytes and PPARγ  
Mesenteric fat‟s role in intestinal fibrosis correlates with PPARγ activity(57,58). PPAR-γ 
affects inflammation/fibrosis in IBD as its activation in visceral mesenteric fat reduces TNF-α 
and leptin expression, while increasing adiponectin(65).  
 
PPARγ activators are efficacious in a variety of experimental models of fibrosis. Specific 
synthetic ligands for PPARγ control fibrosis by down-regulating myofibroblasts proliferation 
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and migration, and inducing apoptosis, inhibiting profibrogenic TGF-β, PDGF and leptin 
while up-regulating anti-fibrogenic HGF and adiponectin, and reducing ECM 
deposition(16,63). The inhibitory effects of adiponectin are mediated by AMP kinase 
activation. Moreover, genetic deletion of adiponectin in mouse fibroblasts abrogated the TGF-
β signalling inhibition by PPARγ agonists. Together, it suggests that the adiponectin/AMP 
kinase pathway is important in ECM regulation and fibrosis. 
 
The importance of crosstalk between mesenteric fat and IBD intestine and its role in 
fibrogenesis is controversial. Further investigations may allow for analysis of mechanisms 
involved in fibrosis and point to potential anti-fibrotic strategies. 
   
Key points 
 „Creeping fat‟ or „fat wrapping‟ is specific for CD; 
 The terminal ileum is most frequently affected by „fat wrapping‟; 
 Intestinal fibrosis is associated with „creeping fat‟; 
 Mesenteric adipose tissue contributes to pro-inflammatory/fibrotic responses. 
Questions  
 What are the adipose-tissue derived pro-inflammatory/fibrotic responses? 
 What is the role of adipokines in fibrosis? 
 Is there an adipose-tissue anti-fibrotic response? 
 How do microbial factors elicit an immune and pro-fibrotic response from adipose 
tissue? 
 Can „creeping fat‟ represent an anti-microbial defense mechanism? 
 
6. GENETIC AND EPIGENETIC FACTORS 
 
IBD fibrosis susceptibility may have genetic and/or epigenetic components. IBD Genome-
wide association studies(GWAS) identified numerous genetic polymorphisms including 
single nucleotide polymorphism-SNP. In 2013 the number of IBD risk loci was 163, whose 
110 are shared between CD and UC, 23 are specific for UC and 30 for CD(66). These 
polymorphisms impact the innate immunity, autophagy, intestinal barrier functions, IL-10 
signalling and adaptive immunity. Some of these polymorphisms may promote the 
development of intestinal fibrosis. 
 
These genetic variations, however, only account for approximately 20% of IBD cases. Other 
genetic mechanisms, therefore, may be involved, including heritable and reversible epigenetic 
alterations, notably DNA methylation and histone modification(66). In addition, miRNAs 
may affect IBD immunity and fibrosis(36). There is thus a need to comprehensively 
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characterize the functional genomic features of IBD and the environmental triggers together 
with specific disease phenotypes. 
 
6.1 Genetics  
IBD fibrosis is dynamic and multifactorial and develops by interactions between genetic and 
environmental factors with different genetic polymorphisms influencing fibrosis in animal 
models and human case-control studies. These suggest that variants of genes encoding 
immunoregulatory proteins, pro- and anti-inflammatory cytokines, and fibrogenic factors may 
impact IBD fibrosis. 
 
NOD2 
The NOD2 gene, on chromosome 16 was one of the first genetic candidate involved in 
intestinal fibrosis. The three variants of NOD2 gene(R702W, G908R, L1007fsinsC) 
contribute as much as 30-50% of CD susceptibility.  
 
There is a genotype/phenotype association between NOD2 variants and fibrostenosing 
disease(20,67). A meta-analysis identified that a single NOD2 variant increased the risk for 
intestinal fibrosis by 8% and up to 41% for 2 variants(67). The combination of NOD2 variants 
and serological markers were associated with complicated disease(20). A large retrospective 
study of 1528 CD patients with >10yrs follow-up, detected increased probability of 
developing stenosing disease with NOD2, Janus kinase(JAK)2 and ATG16L1 mutations(68). 
Furthermore, CD patients carrying NOD2 gene variants have an increased and early need for 
first surgery due to stricturing disease and higher rate of surgical recurrence(69). 
 
The mechanisms that are responsible for the NOD2-induced fibrosis are unknown. This gene 
is important in intestinal autophagy against microbes and, in combination ATG16L1 and TLR 
variants, may contribute to the transcriptional and translational changes causing fibrosis(70). 
Interaction between different genes is also suggested with more fibrostenosing CD in 
individuals carrying the NOD2 genotype and 4G/4G genotype of plasminogen activator 
inhibitor(PAI-I). 
 
ATG16L1 
Autophagy-related-16L1 gene(ATG16L1) variants(rs2241879 and rs2241880) favour 
fibrosis(68). Their impact, however, varies between patients and regions, thus ATG16L1 may 
be complementary to other gene mutations. 
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TLRs 
TLR variants, especially TLR4, are associated with increased fibrostenotic SB CD(20,21). 
Multiple variants in TLR4 also result in liver fibrosis, whereas a TLR7 SNP protects from 
advanced liver inflammation and fibrosis(71).   
 
CX3CR1 gene  
Two polymorphisms(V249I and T280M) of chemokine fractalkine receptor CX3CR1 are 
associated with fibrostenotic CD, particularly in smokers and this is independent of 
NOD2(72,73). 
 
TGF-β 
TGF-β1 is the prototypical fibrogenic molecule, but although, TGF-β1 polymorphisms are 
associated with stricturing CD, and a shorter time to intestinal resection in adults(74), in 
children with IBD, intestinal fibrosis was not linked to four different TGF-β mutations(75).  
                           
Interleukin 23 receptor  
Variants in the interleukin 23 receptor(IL23R) gene are associated with CD fibrosis, with the 
TT genotype of IL23R rs1004819 variant associated with ileal and stricturing CD, but like 
ATG16L1 there are geographical differences(76).  
 
MMPs and TIMPs 
The balance between MMPs and TIMPs is vital in fibrosis. SNPs in genes encoding MMP-1, 
-2, -3, -9, TIMP-1 have been described in CD and the 5T5T genotype at the MMP-3 SNP-
1613 5T/6T increases the chance of stenotic complications in CD(77). 
 
6.2 Epigenetics 
Epigenetics is the study of all heritable, and potentially reversible, genome functional changes 
that do not alter the nucleotide DNA sequence i.e. the regulation of gene expression(66). 
Epigenetics can be further defined as „the inheritance of variation above and beyond 
(epi)changes in the DNA sequence‟ and represents mechanisms by which the environment 
may alter gene expression. 
 
Various epigenetic mechanisms, including DNA methylation, histone modifications (histone 
methylation, acetyilation, phosphorylation, sumoylation/ubiquitination) and formation of 
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particular chromatin structure, play crucial roles in the gene transcriptional expression in 
ECM-producing cells.  
 
ECM degradation is also regulated through epigenetic modulation of matrix-associated 
enzymes. Epigenetic markers may thus be the missing link connecting the IBD internal micro- 
and external macro-environmental exposure to the transcriptome changes associated with 
fibrosis. The epigenetic control of inflammation and fibrosis, in IBD is not fully understood.  
 
DNA methylation 
Numerous intestinal disease-associated DNA-methylations occur in IBD(78). Changes in 
methylation states of IBD-associated genes are associated with gene expression shifts. 
Specific methylation may be associated with IBD where there are distinct DNA methylations 
profiles(1505 CpG sites of 807 genes). One study identified seven CsG sites where 
differential methylation occurred in IBD(78). Moreover, in IBD, subtype-specific changes in 
DNA methylation occurs, identified in several loci within the IL-12/IL-23 pathway(79). 
 
It is unknown, however, how these methylation profiles impact on IBD genes. Demethylation 
of the MD-2 promotor site in the TLR4/MD-2 complex results in increased MD-2 expression, 
while IFN-γ methylation levels correlate with the immune response to microbial 
components(80,81).  
 
Conclusion 
Genetic variations are associated with CD fibrosis, and most are associated with NOD2. Other 
mutations will, undoubtedly, be found, may clarify the complex characterisation and 
subsequent changes in functional genomics. Epigenetic studies in IBD, however, are in their 
infancy and future studies may potentially have high clinical utility, especially in the 
prediction of the future complication of intestinal fibrosis and the impact of therapeutic 
interventions.  
Key points 
 Genetic variants and IBD susceptibility are linked; 
 NOD2 variants, alone or in combination with TLR or ATG16L1 polymorphisms are 
associated with fibrostenotic SB CD. 
 Epigenetic modifications may amplify, or inhibit, the fibrogenic processes. 
Questions  
 Which gene variants alter the risk of IBD fibrosis and how? 
 Which epigenetic modifications primarily affect fibrosis? 
 How does the gut microenvironment and the external macroenvironment interact with 
the genetic/epigenetic factors associated with intestinal fibrosis? 
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7. ANIMAL MODELS 
 
Animal models are essential for dissecting the pathogenetic mechanisms of inflammation-
induced intestinal fibrosis. Understanding the similarities and differences between each model 
and human disease is essential as, currently, no single animal model truly recapitulates the 
chronic, fluctuating, progressive nature of IBD(5).  
 
Animal models addressing intestinal fibrosis can be classified into seven categories: 
spontaneous, chemical-, bacterial-, immune- and radiation-induced, post-operative and gene 
knockout and transgenic models (Table 3). Besides the animal models, several in vitro 
systems are also available. 
 
7.1 Spontaneous Intestinal Fibrosis  
 
SAMP1/Yit mouse 
The SAMP1/Yit mouse is the most representative model of chronic intestinal inflammation, 
as disease develops spontaneously(82). Its similarities with CD include ileal lesions, 
segmental and transmural injury, granulomas and perianal lesions. Microbial factors 
accelerate, but are not essential, for the model. A striking feature is prominent hypertrophy of 
ileal muscularis propria with areas of focal fibrosis that result in segmental stricturing and 
pre-stenotic dilatation. 
 
 The mucosal immunophenotype of ileitis has two distinct phases(83). The induction phase is 
a typical, bacteria-related, Th1 response with no muscular hypertrophy or strictures. After 
week 10, the maintenance/chronic phase is established and is dominated by Th2/IL-13 
responses(83). Alterations in ECM occur with collagen deposition and fibrostenosis. The 
SAMP1/Yit model offers unique opportunities to study induction and perpetuation, of 
inflammation-induced intestinal fibrosis.  
 
7.2 Chemically-Induced Models  
The „chemical‟ models of intestinal inflammation/fibrosis are the most utilized because they 
are easy, reproducible and straightforward.  They involve colonic injury induced by the local 
delivery of an offensive chemical and allow for the study of both inflammatory and mucosal 
repair mechanisms.   
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The mucosal events that follow a chemical insult are, however, not representative of the 
immunological phenomena in IBD and results should be analyzed with caution.   
 
TNBS 
TNBS-induced colitis is the best-characterized murine model of inflammation-induced 
intestinal fibrosis(45). Colorectal colonic fibrosis, lumen stenosis and bowel dilatation 
develops after several doses of TNBS. Fibrosis is associated with elevated mucosal pro-
inflammatory/fibrogenic factor expression and morphological analysis of colonic 
mesenchymal cells reveal distinctive features and enhanced response to IFN- stimulation, 
which primarily increase TIMP-1 expression(45).   
 
Mucosal expression of IL-13 replaces the initial Th1-type response and induces TGF-β1 
expression by week 8-9 post-TNBS administration. Abrogation of IL-13 signalling via soluble 
IL-13R2-Fc, or IL-13R2-specific siRNA prevents TGF-β1 upregulation and fibrosis(84). 
IGF-I and early growth response gene(Egr)-1 are also pivotal in this model.  
 
Fibrosis depends on the presence of inflammation as it is effectively prevented by the 
prophylactic neutralization of the master inflammatory regulator NF-B(45) and by the 
coadministration of retinoic acid, while enhanced by the co-administration of 
indomentacin(47). 
 
DSS 
Dextran sodium sulphate (DSS) is administered in the drinking water resulting in colonic 
injury followed by spontaneous healing. Colonic fibrosis occurs after a single, or repeated 
cycles, of DSS administration and is dependent upon the murine genetic background(85). 
After 5 days of DSS administration, collagen colonic deposition is evident and gradually 
increases with elevations of TGF-1, MMP-2 and -9. This is associated with mucosal 
upregulation of IFN-, TNF-, IL-1β, IL-6, IL-17a and IL-10 mRNA(86).  
 
7.3 Bacteria-Induced Models  
Salmonella  
A post-Salmonella enteric serovar Typhimurium(S typhimurium) infection fibrosis murine 
model was reported and characterized by caecal inflammation and fibrosis(87). At the 
molecular level, TGF-1 and its downstream mediator CTGF, and IGF-1 are upregulated in 
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regions with infecting microorganisms. A strong pro-inflammatory mucosal milieu, consisting 
of TNF-, IFN-, MCP-1, and IL-17 are also detected in infected ceca, providing a link 
between inflammation and fibrosis. This model demonstrates that inflammation precedes 
fibrosis and more importantly that limiting inflammation by early intervention limits fibrosis. 
When a certain pathological stage is reached, however, fibrosis is independent of 
inflammation and non-reversible. A serious drawback of this model is that Salmonella 
infection does not result in fibrosis in humans. 
 
Adherent-invasive Escherichia coli 
Chronic adherent-invasive Escherichia coli infection in streptomycin-treated conventional 
mice induces an active T-helper 17 response, heightened levels of proinflammatory cytokines 
and fibrotic growth factors, with the development of transmural inflammation and 
fibrosis(88). Depletion of CD8+ T cells increases the caecal bacterial load and the level of 
inflammation and intestinal fibrosis in C57BL/6 mice, suggesting that they play a protective 
role. These findings suggest that chronic adherent-invasive Escherichia coli infection results 
in an immunopathology that is similar to that seen in CD.  
 
PG-PS  
An intramural intestinal wall injection induces local inflammation, followed by bowel wall 
thickening and fibrosis with increased TGF-1 and IGF-1 expression(89). Inflammation and 
fibrosis are triggered by products of the commensal intestinal flora and thus allows for the 
study of microbiota-induced fibrosis.   
 
7.4 Immune-Mediated Models 
The T-cell transfer model is the prototypical immune-mediated model, where naive 
CD45RB
high
 CD4+ T cells are injected into SCID mice resulting in severe transmural colonic 
inflammation and mild fibrosis(90). This model, however, has only been used to examine the 
immune-mediated events and not fibrosis. Since in IBD T cells are intimately involved in 
fibrosis, investigation of fibrogenesis in this model should be of use.  
 
7.5 Radiation-Induced Intestinal Fibrosis 
Radiation can cause bowel inflammation and fibrosis, which is similar to CD with 
myofibroblast/SMC proliferation, vascular sclerosis and chronic ulcers(91). Endothelial cell 
dysfunction is key for radiation-induced intestinal fibrosis with prolonged upregulation of 
 27 
fibrogenic cytokines in the irradiated bowel. Ras homologue (Rho) and Rho-associated kinase 
(ROCK) signalling pathways are involved, as are mast cells and their products. 
 
7.6 Post-operative models of fibrosis 
Postoperative anastomotic fibrosis is common, but why it develops is unknown. In IL-10 KO 
mice following ileocecal resection, inflammation-driven small intestinal fibrosis occurs at the 
site of resection and adjacent SB(92). Interestingly, germ-free IL-10 KO mice don‟t develop 
fibrosis, suggesting a role for gut microbiota. As fibrosis occurs proximal to anastomosis, it 
represents an excellent model for the study of cellular and molecular mechanisms of this 
complication. 
 
A new model is the heterotopic transplantation of SB resections in rats(54). Rapid loss of 
crypt structures occurs at day 2 after transplantation followed by lymphocyte infiltration and 
obliteration of the intestinal lumen by fibrosis at day 21, which is associated with increased 
expression of established mediators of fibrosis such as αvβ6 integrin, IL-13, and TGF-β. 
Typical histologic and molecular features of fibrosis are observed in the heterotopic intestinal 
grafts, which suggests, that this new model could be instrumental in studying treatment of 
intestinal fibrosis. 
 
7.7 Gene Knockout and Transgenic Models 
The development of intestinal fibrosis by the manipulation of selected genes represents a 
direct method for determining which specific immune abnormalities may lead to fibrosis. IL-
10-deficient mice develop chronic enterocolitis(93). A typical Th1-dominant inflammatory 
cytokine appears early, whereas in late disease a Th2 profile emerges resulting in ECM 
accumulation. This model could be useful to investigate mucosal fibroblasts in fibrosis. 
 
As TGF-β/Smad signalling is important for fibrosis, disruption of TGFβ/Smad signalling 
reduces intestinal fibrosis(94). Forced intestinal overexpression of TGF1 by an adenoviral 
vector results in inflammation/fibrosis, collagen deposition and myofibroblast infiltration with 
colonic obstruction in 50% of mice(95).  
 
Conclusion 
Animal models are integral to basic and translational research. More importantly, novel anti-
fibrotic therapies can be tested by directly manipulating specific molecular pathways. The 
inherent problems associated with such approaches, however, should be kept in mind:   
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 1.  No animal model truly represents human disease. Chemical models lack the chronic 
nature, while genetically manipulated models have single defects that do not recapitulate the 
polygenetic nature and generalized immune dysregulation. The few spontaneous models may 
thus offer the best opportunity for dissecting the fibrotic pathways. 
 2. As fibrosis primarily is a product of chronic inflammation, it is not easy to separate the 
anti-inflammatory from anti-fibrotic effects of treatments.   
 3. The majority of models demonstrate a dependence on TGF-1 or IL-13 for 
fibrogenesis, but these are most probably complementary.  It is not clear whether these are 
true biological phenomena or reflect current fibrosis-related research.  
 4. The natural history of each model needs to be considered. Different phases of 
inflammation should be recognized, their immunological characteristics identified, and 
temporal and aetiological association with fibrosis defined.  For example, some models 
develop as typical Th1-mediated inflammatory disease but with chronicity shift towards a 
Th2/IL-13 predominant type where fibrosis occurs. It may thus be more appropriate that anti-
fibrotic treatments aim at neutralizing the late, and not the early, responses. By contrast, the 
exact time-point at which fibrogenesis starts is not well defined and it may be much earlier 
than thought, suggesting that therapies used in parallel with anti-inflammatory treatment may 
be appropriate.  
Key points 
 There are few models of intestinal fibrosis; 
 Most IBD animal studies have focused on immunity and inflammation; 
 No single animal model recapitulates human IBD; 
 Similarities and differences between the models and human IBD should be clearly 
delineated; 
 Animal models represent indispensable tools; 
 Findings in experimental models do not always translated into clinical practice. 
Questions  
 Is a standard definition for intestinal fibrosis in models required? 
 Are animal models useful to identify pathogenic events of intestinal fibrosis and to test 
new therapeuties? 
 Do results need to be replicated in different animal models? 
 Are animal models useful to investigate early and late events of intestinal fibrosis? 
 Which in vitro models are more useful and reliable to unravel the complex cellular and 
molecular mechanisms of intestinal fibrosis? 
 
8. CONCLUSION 
 
Intestinal fibrosis is highly complex with the specific molecules determining the balance 
between physiologic repair and excessive ECM accumulation remaining unknown. Strong 
evidence indicates that inflammation triggers fibrosis, which, once established, may progress 
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independently. It is critical, therefore, to elucidate the cellular signals that promote 
fibrogenesis and act independently of inflammatory pathways and the immuno-inflammatory 
response. Defining the cellular and molecular mechanisms involved in intestinal fibrosis is 
key to the development of new therapies. 
 
The concept of intestinal fibrosis has changed from being static and irreversible to a dynamic 
and reversible disease. Novel therapeutic strategies are under investigation to target specific 
steps in fibrogenesis with the aim of reducing, or reversing, IBD fibrosis. One hope is that 
researchers, funding agencies and pharmaceutical industries accelerate their efforts to 
identify, and develop, safe and effective anti-fibrotic therapies. 
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FIGURE LEGENDS 
 
Figure 1. Pathogenetic steps  of intestinal fibrosis in IBD. ROS= reactive oxygen species; 
SMCs= smooth muscle cells;  SEMFs= intestinal subepithelial myofibroblasts; ICC= 
intestitial cells of Cajal; EMT= epithelial-to-mesenchymal transition; EndoMT= endothelial-
to-mesenchimal  transition; ECM= extracellular matrix.  
 
Figure 2. Relationship among several pro-fibrotic and anti-fibrotic mediators in the 
development of fibrosis. IL-13=Interleukin-13; CCL2=monocyte chemoattractant protein-1 
(MCP1); CCL3=macrophage inflammatory protein-1 (MIP1); TGF-=transforming growth 
factor-; CTGF=connective tissue growth factor; PDGF=platelet derived growth factor; IGF-I 
=insulin-like growth factors I; TLR-2,-4= Toll-like receptor-2,-4; miRNA=microRNA; 
EGF=epidermal growth factor; bFGF=basic fibroblast growth factor; ETs=endothelins;  
ACE=angiotensin convertingenzyme; AT-II=angiotensin-II;  mTOR=mammalian target of 
rapamycin; PPAR-= peroxisome proliferator activator receptor-; INF-&β=interferon-&β; 
HGF=hepatic growt factor; ECM= extracellular matrix. 
 
Figure 3. Interaction between profibrotic transforming growth factor-(TGF-) and anti-
fibrotic peroxisome proliferator activator receptor-( PPAR-) factors: need to identify and 
selectively modulate trasduction and transcription signalings of ECM synthesis/degratation 
without to affect other physiological pathways. 
 
Figure 4. Genetic variants and immune responses in Crohn‟s disease patients  may predict the 
risk for  fibrostenosis phenotype and surgery. NOD2=nucleotide oligomerization domain 2; 
TLRs=toll-like receptors; ATG16L1= autophagy-related-16L1 gene; Abs= antibodies; 
Ags=antigens; ASCA =anti-Saccharomyces cerevisiae antibodies; I2=pseudomonas-
associated sequence I2; OmpC=outer membrane porin C of Escherichia coli; CBir1= bacterial 
flaggelin cBir1. 
 
 
 
 
 38 
 
Table 1.Molecules involved in intestinal fibrosis 
 
FIBROGENIC                  
-Transforming growth factor- (TGF- ) 
-Smad2/3 proteins 
-Activin A 
-Connective tissue growth factor (CTGF) 
-Platelet derived growth factor (PDGF) 
-Insulin-like growth factors (IGF-I and II) 
-Epidermal growth factor (EGF)  
-Basic fibroblast growth factor (bFGF) 
-Cytokines (IL-1β, IL-4, IL-6, IL-13, IL-17,    
IL-21, IL-22, IL-23, IL-33, TNF-) 
-CC- and  CXC-chemokines  (CCL2, 
CCL3, CCL4, CCL20) 
-Reactive Oxygen Species (ROS) 
-Integrins (αVβ6, αVβ8) 
-Mammalian Target Of Rapamycin (mTOR) 
-PAMPs and TLRs  (TLR2&4 ligands) 
-DAMPs (DNA, RNA, ATP, HMGB1, uric acid, 
fragments of ECM) 
-Hedgehog (Hh) signalling pathway 
-Wnt– β-catenin signalling pathway 
-Advanced glycation endproducts receptor 
(RAGE) 
- Notch signalling pathway 
- MicroRNAs (miRNAs) 
- Endoplasmic reticulum (ER) stress 
-Vascular endothelial growth factor (VEGF) 
-Endothelins (ET-1) 
-Angiotensin Converting Enzyme (ACE)  
-Angiotensin-II (AT-II) 
-Norepinephrine 
-Thrombospondin-1,2 
-Leptin 
-Tissue Inhibitor of Metalloproteinases  
(TIMPs) 
 
ANTI-FIBROGENIC  
 -Peroxisome Proliferator Activator    
Receptor- (PPAR-) 
-Interferon- (INF-)  
-Interferon- (INF-) 
-IL-7, IL-10, IL-12 
-Smad7 protein 
-PGE2 
-Hepatocyte growth factor (HGF) 
-Adiponectin 
-Klotho 
-Nitric Oxide (NO) 
-Relaxin 
-Matrix Metalloproteinases (MMPs) 
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ECM MOLECULES 
     Collagens 
  
 
     Glycoproteins 
  
 
 
 
 
 
     Proteoglycans 
 
 
 
 
PROTEINS MODIFYING ECM  
     Matrix Metalloproteinases 
 
 
 
 
 
     
      
Tissue inhibitor of Metalloproteinases 
 
 
• Fibrillar Type Collagens I - III - V 
• Non-Fibrillar Collagen Type IV 
 
• Laminin 
• Entactin/nidogen 
• Fibronectin/vitronectin 
• Tenascin 
• Sparc/BM40 
• Thrombospondin/osteopontin 
 
• Glycosaminoglycans (Hyaluronic Acid)  
• Heparan Sulfate  
• Chondroitin Sulfate  
• Perlecan 
 
• Collagenases (MMP-1, -8, -13, -18) 
• Gelatinases (MMP-2, -9) 
• Stromelysins (MMP-3, 10, -11) 
• Matrilysin (MMP-7)  
• Elastase (MMP-12) 
• Membrane types (MT-1,-2,-3,-4,-5,-   6-MM; 
namely MMP-14, MMP-15, MMP-16, MMP17, 
MMP-24, MMP-25, respectively) 
• Others (MMP-19, -20, -21, -22, -23, 26, -27, -28) 
 
• TIMP-1,  -2, -3, -4 
 
 
 
 
 
 
 
 
 
 
 
Table  2. ECM molecules  and MMP/TIM-system in intestinal fibrosis 
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Table 3. Experimental Models to study IBD Fibrosis 
ANIMAL MODELS 
 
Spontaneous 
     SAMP1/Yit mouse 
 
Chemical-Induced 
     2, 4, 6-trinitrobenzenesulphonic acid (TNBS)  
     Dextran sodium sulphate (DSS) 
 
Bacteria-Induced 
      Salmonella 
     Escherichia coli 
     Peptidoglycan-polysaccharide (PG-PS) 
 
Immune-Mediated  
 
Radiation-Induced 
 
Post-Operative 
            
Gene Knockout  and Transgenic  
 
CELL CULTURE SYSTEMS 
 
CCell lines cultures 
 
Human cell primary cultures from IBD pts 
     Fibroblasts 
     Myofibroblasts 
     Smooth muscle cells 
     Endothelial cells 
  
Microvescicles 
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Figure 1. Pathogenetic steps  of intestinal fibrosis in IBD. ROS= reactive oxygen species; 
SMCs= smooth muscle cells;  SEMFs= intestinal subepithelial myofibroblasts; ICC= 
intestitial cells of Cajal; EMT= epithelial-to-mesenchymal transition; EndoMT= endothelial-
to-mesenchimal  transition; ECM= extracellular matrix.  
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Figure 2. Relationship among several pro-fibrotic and anti-fibrotic mediators in the 
development of fibrosis. IL-13=Interleukin-13; CCL2=monocyte chemoattractant protein-1 
(MCP1); CCL3=macrophage inflammatory protein-1 (MIP1); TGF-=transforming growth 
factor-; CTGF=connective tissue growth factor; PDGF=platelet derived growth factor; IGF-I 
=insulin-like growth factors I; TLR-2,-4= Toll-like receptor-2,-4; miRNA=microRNA; 
EGF=epidermal growth factor; bFGF=basic fibroblast growth factor; ETs=endothelins;  
ACE=angiotensin convertingenzyme; AT-II=angiotensin-II;  mTOR=mammalian target of 
rapamycin; PPAR-= peroxisome proliferator activator receptor-; INF-&β=interferon-&β; 
HGF=hepatic growt factor; ECM= extracellular matrix. 
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Figure 3. Interaction between profibrotic transforming growth factor-(TGF-) and anti-
fibrotic peroxisome proliferator activator receptor-( PPAR-) factors: need to identify and 
selectively modulate trasduction and transcription signalings of ECM synthesis/degratation 
without to affect other physiological pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44 
 
 
 
 
 
 
 
 
 
 
Figure 4. Genetic variants and immune responses in Crohn‟s disease patients  may predict the 
risk for  fibrostenosis phenotype and surgery. NOD2=nucleotide oligomerization domain 2; 
TLRs=toll-like receptors; ATG16L1= autophagy-related-16L1 gene; Abs= antibodies; 
Ags=antigens; ASCA =anti-Saccharomyces cerevisiae antibodies; I2=pseudomonas-
associated sequence I2; OmpC=outer membrane porin C of Escherichia coli; CBir1= bacterial 
flaggelin cBir1. 
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